1. Daley CL, Iaccarino JM, Lange C, Cambau E, Wallace RJ Jr, Andrejak C, Böttger EC, Brozek J, Griffith DE, Guglielmetti L, Huitt GA, Knight SL, Leitman P, Marras TK, Olivier KN, Santin M,
Stout JE, Tortoli E, van Ingen J, Wagner D, Winthrop KL. Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline. Eur
Respir J. 2020 Jul 7;56(1):2000535. doi: 10.1183/13993003.00535-2020. PMID: 32636299; PMCID: PMC8375621.
2. Prevots DR, Marshall JE, Wagner D, Morimoto K. Global Epidemiology of Nontuberculous Mycobacterial Pulmonary Disease: A Review. Clin Chest Med. 2023;44(4):675-721. doi: 10.1016/j.
ccm.2023.08.012.
3. Griffith DE. Nontuberculous Mycobacterial Disease: A Comprehensive Approach to Di- agnosis and Management. 1st ed. Humana Cham; 2019.
4. Bryant JM, Grogono DM, Rodriguez-Rincon D, Everall I, Brown KP et all Emergence and spread of a human-transmissible multidrug-resistant nontuberculous mycobacterium. Science (New
York, NY). 2016;354(6313):751–7. https://doi. org/10.1126/science.aaf8156. )
5. Schildkraut JA, Coolen JPM, Severin H, et al. MGIT enriched shotgun metagenomics for routine identifi- cation of nontuberculous mycobacteria: a route to personalized health care. J Clin
Microbiol 2023; 61(3):e0131822.
6. Dahl VN, Mølhave M, Fløe A, et al. Global trends of pulmonary infections with nontuberculous mycobacteria: a systematic review. Int J Infect Dis 2022;125: 120–31.
7. Kumar K, Loebinger MR. Nontuberculous Mycobacterial Pulmonary Disease: Clinical Epidemiologic Features, Risk Factors, and Diagnosis: The Nontuberculous Mycobacterial Series. Chest.
2022 Mar;161(3):637-646. doi: 10.1016/j.chest.2021.10.003. Epub 2021 Oct 8. PMID: 34627854.
8. Gardner AI, McClenaghan E, Saint G, McNamara PS, Brodlie M, Thomas MF. Epidemiology of nontuberculous mycobacteria infection in children and young people with cystic fibrosis:
analysis of UK cystic fibrosis registry. Clin Infect Dis 2019;68:731–7.
9. Qvist T, Gilljam M, Jönsson B, Taylor-Robinson D, Jensen-Fangel S, Wang M, et al. Epidemiology of nontuberculous mycobacteria among patients with cystic fibrosis in Scandinavia. J Cyst
Fibros 2015;14:46–52.
10. Lee SJ, Ju S, You JW, Jeong YY, Lee JD, Kim HC, et al. Trends in the prevalence of non-TB mycobacterial infection in patients with non-cystic fibrosis bronchiecta- sis in South Korea, 2012–
2016. Chest 2021;159:959–62.
11. Pyarali FF, Schweitzer M, Bagley V, Salamo O, Guerrero A, Sharifi A, et al. Increasing non-tuberculous mycobacteria infections in veterans with COPD and association with increased risk of
mortality. Front Med (Lausanne) 2018;5:311.
12. Dahl VN, Mølhave M, Fløe A, van Ingen J, Schön T, Lillebaek T, Andersen AB, Wejse C. Global trends of pulmonary infections with nontuberculous mycobacteria: a systematic review. Int J
Infect Dis. 2022 Dec;125:120-131. doi: 10.1016/j.ijid.2022.10.013. Epub 2022 Oct 13. PMID: 36244600.
13. Prevots DR, Marras TK, Wang P, Mange KC, Flume PA. Hospitalization Risk for Medicare Beneficiaries With Nontuberculous Mycobacterial Pulmonary Disease. Chest. 2021 Dec;160(6):2042-
2050. doi: 10.1016/j.chest.2021.07.034. Epub 2021 Jul 24. PMID: 34314672; PMCID: PMC8727849.
14. Thomson RM, Furuya-Kanamori L, Coffey C, Bell SC, Knibbs LD, Lau CL. Influence of climate variables on the rising incidence of nontuberculous mycobac- terial (NTM) infections in
Queensland, Australia 2001–2016. Sci Total Environ 2020;740.
15. Kılbaş İ, Uzun M. Latest status of non-tuberculous mycobacteria prevalence in Türkiye and the world: Systematic review. Tuberk Toraks. 2023 Dec;71(4):408-419. English. doi: 10.5578/
tt.20239609. PMID: 38152011.
16. Van der Laan R, Snabilié A, Obradovic M. Meeting the challenges of NTM-PD from the perspective of the organism and the disease process: innovations in drug development and delivery.
Respir Res. 2022 Dec 24;23(1):376. doi: 10.1186/s12931-022-02299-w. PMID: 36566170; PMCID: PMC9789522.
17. Loebinger MR, Quint JK, van der Laan R, Obradovic M, Chawla R, Kishore A, van Ingen J. Risk Factors for Nontuberculous Mycobacterial Pulmonary Disease: A Systematic Literature Review
and Meta-Analysis. Chest. 2023 Nov;164(5):1115-1124. doi: 10.1016/j.chest.2023.06.014. Epub 2023 Jun 17. PMID: 37429481.
18. Odashima K, Kagiyama N, Kanauchi T, Ishiguro T, Takayanagi N. Incidence and etiology of chronic pulmonary infections in patients with idiopathic pulmonary fibrosis. PLoS One.
2020;15(4):e0230746.
19. Kim SJ, Yoon SH, Choi SM, et al. Characteristics associated with progression in patients with of nontuberculous mycobacterial lung disease: a prospective cohort study. BMC Pulm Med.
2017;17(1):5.
20. Adjemian J, Olivier KN, Seitz AE, Falkinham JO, Holland SM, Prevots DR. Spatial clusters of nontuberculous mycobacterial lung disease in the United States. Am J Respir Crit Care Med.
2012;186(6): 553-558.
21. Reich Jerome M, Johnson Richard E: Mycobacterium avium complex pulmonary disease presenting as an isolated lingular or middle lobe pattern: the Lady Windermere syndrome. Chest
101:1605-1609, 1992).
22. Nguyen I, Green O, Modahl L. Nontuberculous Mycobacterial Pulmonary Disease: A Clinical and Radiologic Update. Semin Roentgenol. 2022 Jan;57(1):75-89. doi: 10.1053/j.ro.2021.10.008.
Epub 2021 Oct 27. PMID: 35090712
23. Weiss CH, Glassroth J. Pulmonary disease caused by nontuberculous mycobacteria. Expert Rev Respir Med. 2012 Dec;6(6):597-612; quiz 613. doi: 10.1586/ers.12.58. Erratum in: Expert Rev
Respir Med. 2013 Apr;7(2):195-6. PMID: 23234447.
24. Jankovic M, Sabol I, Zmak L, Jankovic VK, Jakopovic M, Obrovac M, Ticac B, Bulat LK, Grle SP, Marekovic I, Samarzija M, van Ingen J. Microbiological criteria in non-tuberculous mycoba-
cteria pulmonary disease: a tool for diagnosis and epidemiology. Int J Tuberc Lung Dis. 2016 Jul;20(7):934-40. doi: 10.5588/ijtld.15.0633. PMID: 27287647.
25. Zweijpfenning SMH, Ingen JV, Hoefsloot W. Geographic Distribution of Nontuberculous Mycobacteria Isolated from Clinical Specimens: A Systematic Review. Semin Respir Crit Care Med.
2018 Jun;39(3):336-342. doi: 10.1055/s-0038-1660864. Epub 2018 Aug 2. PMID: 30071548.
26. Hwang JA, Kim S, Jo KW, Shim TS. Natural history of Mycobacterium avium com plex lung disease in untreated patients with stable course. Eur Respir J 2017; 49:1600537
27. Gochi M, Takayanagi N, Kanauchi T, Ishiguro T, Yanagisawa T, Sugita Y. Retrospective study of the predictors of mortality and radiographic deterioration in 782 patients with nodular/bron-
chiectatic Mycobacterium avium complex lung disease. BMJ Open 2015; 5:e008058.
28. Hayashi M, Takayanagi N, Kanauchi T, Miyahara Y, Yanagisawa T, Sugita Y. Prognostic factors of 634 HIV-negative patients with Mycobacterium avium complex lung disease. Am J Respir Crit
Care Med 2012; 185:575–83.
29. Babalık A, Kuyucu T, Ordu EN, Ernam D, Partal M, Köksalan K. Non-tuberculous mycobacteria infection: 75 cases. Tuberk Toraks. 2012;60(1):20-31. doi: 10.5578/tt.2543. PMID: 22554363.
30. Kılıçaslan Z, Kuyucu T, Babalik A, Özkan G, Z. K. Bingöl, E. N.Ordu, M.Partal, K. Köksalan Akciğerde Tüberküloz Dışı Mikobakteri Hastalığı: 42 Vakanın Retrospektif AnaliziTurkiye Klinikleri
J Med Sci. 2013;33(3):854-67 doi: 10.5336/medsci.2012-32048
31. Babalik A, Koç EN, Sekerbey HG, Dönmez GE, Balikci A, Kilicaslan Z. Nontuberculous mycobacteria isolation from sputum specimens: A retrospective analysis of 1061 cases. Int J Mycoba-
cteriol. 2023 Jan-Mar;12(1):55-65. doi: 10.4103/ijmy.ijmy_10_23. PMID: 36926764.
32. Pasipanodya JG, Ogbonna D, Deshpande D, Srivastava S, Gumbo T. Meta-analyses and the evidence base for microbial outcomes in the treatment of pulmonary Mycobacterium avium-int-
racellulare complex disease. J Antimicrob Chemother. 2017 Sep 1;72(suppl_2):i3-i19. doi: 10.1093/jac/dkx311. PMID: 28922813.
33. Moon SM, Park HY, Kim SY, Jhun BW, Lee H, Jeon K, Kim DH, Huh HJ, Ki CS, Lee NY, Kim HK, Choi YS, Kim J, Lee SH, Kim CK, Shin SJ, Daley CL, Koh WJ. Clinical Characteristics, Tre-
atment Outcomes, and Resistance Mutations Associated with Macrolide-Resistant Mycobacterium avium Complex Lung Disease. Antimicrob Agents Chemother. 2016 Oct 21;60(11):6758-
6765. doi: 10.1128/AAC.01240-16. PMID: 27572413; PMCID: PMC5075083.
34. Griffith DE, Eagle G, Thomson R, et al; CONVERT Study Group. Amikacin liposome inhalation suspension for treatment-refractory lung disease caused by Mycobacterium avium complex
(CONVERT). a prospective, open-label, randomized study. Am J Respir Crit Care Med 2018; 198:1559–69.
35. Jhun BW, Yang B, Moon SM, et al. Amikacin inhalation as salvage therapy for refractory nontuberculous mycobacterial lung disease. Antimicrob Agents Chemother 2018; 62:e00011–18.
36. Santin M, Dorca J, Alcaide F, et al. Long-term relapses after 12-month treatment for Mycobacterium kansasii lung disease. Eur Respir J 2009; 33:148–52.
37. Diel R, Ringshausen F, Richter E, Welker L, Schmitz J, Nienhaus A. Microbiological and clinical outcomes of treating non-Mycobacterium avium complex nontuberculous mycobacterial
pulmonary disease: a systematic review and meta-analysis. Chest 2017; 152:120–42.
38. Varadi RG, Marras TK. Pulmonary Mycobacterium xenopi infection in non-HIV- infected patients: a systematic review. Int J Tuberc Lung Dis 2009; 13:1210–8.
39. Jenkins PA, Campbell IA, Banks J, Gelder CM, Prescott RJ, Smith AP. Clarithromycin vs ciprofloxacin as adjuncts to rifampicin and ethambutol in treating opportunist mycobacterial lung
diseases and an assessment of Mycobacterium vaccae immunotherapy. Thorax 2008; 63:627–34.
40. Tortoli E, Kohl TA, Trovato A, Garcia MJ, Leao SC, Baldan R, Campana S, Cariani L, Colombo C, Costa D, Pizzamiglio G, Rancoita PM, Russo MC, Simonetti TM, Sottotetti S, Taccetti G,
Teri A, Niemann S, Cirillo DM, Brown-Elliott BA, Wallace Jr. RJ. Emended description of Mycobacterium abscessus, Mycobacterium abscessus subsp. abscessus, Mycobacterium abscessus subsp.
bolletii and designation of Mycobacterium abscessus subsp. massiliense subsp. nov. Int J Syst Evol Microbiol. 2016
41. Pasipanodya JG, Ogbonna D, Ferro BE, et al. Systematic review and meta-analyses of the effect of chemotherapy on pulmonary Mycobacterium abscessus outcomes and disease recurrence. Anti-
microb Agents Chemother 2017; 61:e01206-17.
42. Koh WJ, Jeon K, Lee NY, Kim B-J, Kook Y-H, Lee S-H, Park Y-K, Kim CK, Shin SJ, Huitt GA, Daley CL, Kwon OJ. Clinical significance of differentiation of Mycobacterium massiliense from
Mycobacterium abscessus. Am J RespirCrit Care Med. 2011;183:405–10.
43. Harada T, Akiyama Y, Kurashima A, Nagai H, Tsuyuguchi K, Fujii T, Yano S, Shigeto E, Kuraoka T, Kajiki A, Kobashi Y, Kokubu F, Sato A, Yoshida S, Iwamoto T, Saito H. Clinical and micro-
biological differences between Mycobacterium abscessus and Mycobacterium massiliense lung diseases. J Clin Microbiol. 2012;50(11):3556–61.
44. van Ingen J, Aksamit T, Andrejak C, et al. Treatment outcome definitions in nontuberculous mycobacterial pulmonary disease: an NTM-NET consensus statement. Eur Respir J 2018; 51:
1800170 [https://doi.org/10.1183/13993003.00170-2018].
45. Cheng LP, Chen SH, Lou H, Gui XW, Shen XN, Cao J, Sha W, Sun Q. Factors Associated with Treatment Outcome in Patients with Nontuberculous Mycobacterial Pulmonary Disease: A Large
Population-Based Retrospective Cohort Study in Shanghai. Trop Med Infect Dis. 2022 Feb 15;7(2):27. doi: 10.3390/tropicalmed7020027. PMID: 35202222; PMCID: PMC8876156.
46. Jhun BW, Moon SM, Jeon K, Kwon OJ, Yoo H, Carriere KC, Huh HJ, Lee NY, Shin SJ, Daley CL, Koh WJ. Prognostic factors associated with long-term mortality in 1445 patients with nontu-
berculous mycobacterial pulmonary disease: a 15-year follow-up study. Eur Respir J. 2020 Jan 2;55(1):1900798. doi: 10.1183/13993003.00798-2019. PMID: 31619468.
47. Lee BY, Kim S, Hong YK, et al. Risk factors for recurrence after successful treatment of Mycobacterium avium complex lung disease. Antimicrob Agents Chemother. 2015;59:2972–7.
48. Boyle DP, Zembower TR, Reddy S, Qi C. Comparison of clinical features, virulence, and relapse among Mycobacterium avium complex species. Am J Respir Crit Care Med. 2015;191:1310–7.
49. Boyle DP, Zembower TR, Qi C. Relapse versus reinfection of Mycobacterium avium complex pulmonary disease. Patient characteristics and macrolide susceptibility. Ann Am Thorac Soc.
2016;13:1956–61
50. Daniel-Wayman S, Abate G, Barber DL, et al. Advancing translational science for pulmonary NTM infections: a roadmap for research. Am J Respir Crit Care Med 2019; 99:947–51.